Get the Stockscreener App
0.622
4.09%
-0.0265
Pre-market:
.63
0.008
+1.29%
Vyne Therapeutics Inc stock is traded at $0.622, with a volume of 551.18K.
It is down -4.09% in the last 24 hours and down -7.16% over the past month.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
See More
Previous Close:
$0.6485
Open:
$0.649
24h Volume:
551.18K
Relative Volume:
3.17
Market Cap:
$20.75M
Revenue:
$454.00K
Net Income/Loss:
$-21.72M
P/E Ratio:
-1.1654
EPS:
-0.5337
Net Cash Flow:
$-25.74M
1W Performance:
-5.56%
1M Performance:
-7.16%
6M Performance:
+72.78%
1Y Performance:
-30.84%
1-Day Range:
$0.61
$0.6577
1-Week Range:
$0.61
$0.6738
52-Week Range:
$0.2805
$1.96
Vyne Therapeutics Inc Stock (VYNE) Company Profile
Name
Vyne Therapeutics Inc
Sector
Industry
Phone
800-775-7936
Address
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Compare VYNE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
0.622 | 20.75M | 454.00K | -21.72M | -25.74M | -0.5337 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-25 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-18-24 | Initiated | BTIG Research | Buy |
| Dec-06-21 | Resumed | H.C. Wainwright | Buy |
Vyne Therapeutics Inc Stock (VYNE) Latest News
VYNE (VYNE) merger with Yarrow: $100M financing, 35.8441 exchange ratio - Stock Titan
Zhang Xiaofan discloses 1.87M shares (5.6%) in VYNE Therapeutics (VYNE) - Stock Titan
VYNE Therapeutics (VYNE) Edges Higher in Quiet Trading, Testing Key Resistance at $0.69New Listing Stocks - newsline.com
VYNE Therapeutics (VYNE) Consolidates Near Support After Slight PullbackMACD Signal Stocks - newsline.com
[Form 4] VYNE Therapeutics Inc. Insider Trading Activity - Stock Titan
VYNE Therapeutics (VYNE) Posts Modest Gain, Holds Above Key SupportHedge Fund Favorites - newsline.com
VYNE Therapeutics (VYNE) Edges Lower as Shares Test Key Support Near $0.65Standard Deviation - thelegaladvocate.com
VYNE Highlights Yarrow Merger Strategy and Endocrine Pipeline - TipRanks
VYNE to Advance YB-101 into Phase 2 in Q2 2026; $200M Raised, Phase 2a Readout Expected H2 2027 - TradingView
Yarrow reverse merger refocuses VYNE (NASDAQ: VYNE) with $200M war chest - Stock Titan
VYNE Therapeutics (VYNE) price target decreased by 38.46% to 2.04 - MSN
VYNE SEC FilingsVyne Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Nantahala (NASDAQ: VYNE) reports 2,000,000-share stake representing 6.00% - Stock Titan
Yarrow merger to refocus VYNE (NASDAQ: VYNE) with $200M financing - Stock Titan
MSN Money - MSN
TradingKey - TradingKey
Vyne Therapeutics Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
The regulatory exposure in VYNE Therapeutics (VYNE) results | Q4 2025: Earnings Beat EstimatesNon-GAAP Earnings - The Legal Advocate
VYNE Therapeutics (NASDAQ: VYNE) to become Yarrow Bioscience after merger - Stock Titan
VYNE Therapeutics Inc. (VYNE) beats Q4 2025 EPS expectations significantly, yet shares edge slightly lower in today's trading.Special Dividend - UBND thành phố Hải Phòng
VYNE Therapeutics Inc. (VYNE) reports narrower Q4 2025 loss than estimates, yet shares dip slightly in today’s trading.Post Announcement - Xã Vĩnh Công
VYNE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
VYNE Therapeutics (VYNE) Stock: Market Structure Shift (+3.21%) 2026-04-20Swing Entry Points - newser.com
Is VYNE Therapeutics (VYNE) stock suitable for new investors (Technical Weakness) 2026-04-18Sell Signals - UBND thành phố Hải Phòng
Death Cross: Is VYNE Therapeutics Inc a play on infrastructure spending2026 Movers & Weekly Momentum Stock Picks - baoquankhu1.vn
Market Pulse: Can VYNE Therapeutics Inc expand its profit margins2026 Retail & Weekly High Return Forecasts - baoquankhu1.vn
Breakout Watch: Can VYNE Therapeutics Inc deliver consistent dividends2026 Big Picture & Real-Time Market Sentiment Reports - baoquankhu1.vn
Layoff Watch: Can VYNE Therapeutics Inc sustain earnings growthMarket Performance Report & Momentum Based Trading Signals - baoquankhu1.vn
How does VYNE Therapeutics (VYNE) Stock react to Fed policy | Price at $0.61, Down 0.57%Crowd Breakout Signals - Newser
Weekly Earnings: Is VYNE Therapeutics Inc stock showing strong momentumWeekly Loss Report & Community Trade Idea Sharing Platform - baoquankhu1.vn
Aug PostEarnings: What analysts say about VYNE Therapeutics Inc stockEarnings Overview Report & Real-Time Market Trend Scan - baoquankhu1.vn
Is VYNE Therapeutics (VYNE) Stock exposed to global risks | Price at $0.61, Up 2.53%Sentiment Shift - newsline.com
Published on: 2026-04-08 14:06:22 - baoquankhu1.vn
Rate Cut: What are analysts price targets for VYNE Therapeutics Inc2026 Big Picture & Verified Trade Idea Suggestions - baoquankhu1.vn
VYNE Stock Analysis: VYNE Therapeutics Inc. $0.6 Biotech Minor Dip Stock Review - The Legal Advocate
VYNE (VYNE) CFO has 4,007 shares withheld to cover RSU taxes - Stock Titan
VYNE Therapeutics (VYNE) CSO covers taxes with 2,876 shares - Stock Titan
VYNE (VYNE) legal chief has 4,007 shares withheld to cover RSU taxes - Stock Titan
VYNE (NASDAQ: VYNE) CEO stock withheld to cover RSU tax bill - Stock Titan
Vyne Therapeutics Inc Stock (VYNE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):